We estimate that the CEO & Director of CRESCENT BIOPHARMA, INC. ($CBIO), Joshua Brumm, received a compensation of $13,116,834 in 2025.
These estimates are based on a new DEF14A filing, filed with the SEC on April 21, 2026. Note that parsing errors may occur.
You can track $CBIO on Quiver Quantitative's $CBIO stock dashboard.
$CBIO Stock Insider Trading Activity
$CBIO Stock insiders have traded $CBIO stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CBIO stock by insiders over the last 6 months:
- FUNDS MANAGEMENT LLC FAIRMOUNT purchased 1,360,000 shares for an estimated $18,237,600
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CBIO Stock Hedge Fund Activity
We have seen 38 institutional investors add shares of $CBIO Stock stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 2,718,834 shares (+192.2%) to their portfolio in Q4 2025, for an estimated $32,245,371
- FCPM III SERVICES B.V. added 1,677,852 shares (+inf%) to their portfolio in Q4 2025, for an estimated $19,899,324
- VESTAL POINT CAPITAL, LP added 1,500,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $17,790,000
- BVF INC/IL added 1,360,900 shares (+98.1%) to their portfolio in Q4 2025, for an estimated $16,140,274
- FAIRMOUNT FUNDS MANAGEMENT LLC added 1,360,000 shares (+98.0%) to their portfolio in Q4 2025, for an estimated $16,129,600
- VR ADVISER, LLC added 745,712 shares (+53.7%) to their portfolio in Q4 2025, for an estimated $8,844,144
- ADAR1 CAPITAL MANAGEMENT, LLC added 606,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $7,187,160
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CBIO Stock Analyst Ratings
Wall Street analysts have issued reports on $CBIO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 01/21/2026
To track analyst ratings and price targets for $CBIO Stock, check out Quiver Quantitative's $CBIO forecast page.
$CBIO Stock Price Targets
Multiple analysts have issued price targets for $CBIO recently. We have seen 2 analysts offer price targets for $CBIO in the last 6 months, with a median target of $28.5.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $22.0 on 03/02/2026
- Brad Canino from Guggenheim set a target price of $35.0 on 01/21/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
